Novo invests $100M in Denmark plant; Alliance wants $200M more for FDA budget; Sagent has $500M for new products;

@FiercePharma: Top-read FP news yesterday: CA panel shivs Gilead's Sovaldi on price, suggests focusing it on sickest hep C patients. Story | Follow @FiercePharma

@TracyStaton: In other India news, Dr. Reddy's pulls 58K bottles of generic Prevacid on microbial contamination. More from Reuters | Follow @TracyStaton

@EricPFierce: Pharma cargo theft are on the rise again with a 50% bump in truckload rip-offs. News | Follow @EricPFierce

@CarlyHFierce: On that note, here's a story I wrote yesterday about dying cattle (and Merck). Article | Follow @CarlyHFierce

> Novo Nordisk ($NVO) will invest about $100 million in a purification plant in Denmark to make more ingredients for its diabetes drugs. News

>  The Alliance for a Stronger FDA is asking Congress to raise the FDA budget next year by $200 million to $2.784 billion. Release

> India's Supreme Court ruled in favor of a public interest investigation into whether Ranbaxy Laboratories supplied adulterated drugs in the country. More

> Generic injectable drugmaker Sagent Pharmaceuticals is looking to spend up to $500 million on products to shore up its portfolio. Story

> FDA Commissioner Margaret Hamburg told Congress that the FDA is working with the FTC and the National Coordinator for Health Information Technology to create a mandated framework for regulating healthcare IT. Story

Medical Device News

@FierceMedDev: Another med tech IPO reveal, though K2M hinted in Jan. that this was coming. S-1 | Follow @FierceMedDev

@MarkHFierce: Boston Scientific  isn't giving up on bare metal stents, not by a long shot. Smart move. Story | Follow @MarkHFierce

@MichaelGFierce: Mallinckrodt's U.S. pain drug approval brings Depomed a $10M delivery tech milestone. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Breathing machines made from aquarium pumps could boost preemie survival rates, say researchers at Rice University. Article | Follow @EmilyWFierce

> Stentys touts a revenue bump and cash to burn for its U.S. push. More

> Hologic adds a COO, loses a CFO in a C-level shakeup. Story

> Sorin snatches up a Florida manufacturer's cardiac-lead business for $20M. News

> French surgeons perform closed-heart surgery using a nitinol stent. Item

Biotech News

@FierceBiotech: A who's-that of biotechs snag $119M as the IPO market thunders on. More | Follow @FierceBiotech

@JohnCFierce: Leerink's Liang is reducing price target on Aveo. The CMO has left. Execs giving up on a program, credibility is shot. | Follow @JohnCFierce

@DamianFierce: U.K. joins the 'breakthrough' bandwagon with new fast-track program. Story | Follow @DamianFierce

@EmilyMFierce: STAP stem cell scientists criticized by RIKEN for "inappropriate" behavior. No intentional misconduct ID'd so far. Story via LA Times | Follow @EmilyMFierce

> Chelsea Therapeutics and the return of pharma's phantom checkbook. Article

> Time, distance and the new world of online business news. Opinion

And Finally... Author Barry Werth who wrote The Billion Dollar Molecule: The Quest for the Perfect Drug, about the quest by Vertex Pharmaceuticals ($VRTX) to bring a drug to market, is back 20 years later with a book on the relationship between drugs and money. Review

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.